Showing results (31-40 of 36) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
BMC Cancer|June 30, 2007
Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II studyBernd Gagel, Marc Piroth, Michael Pinkawa, et al.International Journal of Radiation Oncology, Biology, Physics|January 2, 2007
Active breathing control (ABC): determination and reduction of breathing-induced organ motion in the chestBernd Gagel, Cengiz Demirel, Aline Kientopf, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|October 14, 2004
pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxiaBernd Gagel, Patrick Reinartz, Ercole Dimartino, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 5, 2006
Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I studyBernd Gagel, Marc Piroth, Michael Pinkawa, et al.BMC Cancer|March 7, 2006
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility studyBernd Gagel, Patrick Reinartz, Cengiz Demirel, et al.BMC Cancer|June 30, 2007
pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?Bernd Gagel, Marc Piroth, Michael Pinkawa, et al.Pageof 4